InvestSMART

Tryptamine Therapeutics Limited (ASX:TYP)

ALERT: Price-sensitive ASX Announcement for TYP
Current share price for TYP : $0.034 -0.004 (-10.53%)+
Announcement
Release
5 Nov 2025 9:38AM
Price at Release
$0.038
Full Release
download
Summary
Tryptamine Therapeutics Limited (Tryp), a clinical-stage biotechnology company based in Melbourne, announced it has raised $6.1 million from sophisticated investors to accelerate the development of its lead program, TRP-8803, an intravenous formulation of psilocin. The funds, gathered through the issuance of approximately 179 million shares at $0.034 each, will support clinical trials, including a world-first trial targeting Binge Eating Disorder in collaboration with Swinburne University, and further development into other neuropsychiatric indications. The investment also aims to expedite TRP-8803's path to commercial readiness, focusing on manufacturing and regulatory processes. Strong backing was noted from existing investors and board members, reflecting confidence in the company's strategic direction and growth potential.
Key Points
  • Raised $6.1 million through share issuance.
  • Funds to accelerate TRP-8803 clinical trials.
  • World-first trial with Swinburne University for Binge Eating Disorder.
  • Support from existing investors and board members.
  • Focus on neuropsychiatric conditions.
  • Advancing TRP-8803's commercial readiness.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.